Literature DB >> 16378690

The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression.

Brian Carpenter1, Catriona MacKay, Ayham Alnabulsi, Morven MacKay, Colin Telfer, William T Melvin, Graeme I Murray.   

Abstract

The heterogeneous nuclear ribonucleoproteins (hnRNP) are a family of proteins which share common structural domains, and extensive research has shown that they have central roles in DNA repair, telomere biogenesis, cell signaling and in regulating gene expression at both transcriptional and translational levels. Through these key cellular functions, individual hnRNPs have a variety of potential roles in tumour development and progression including the inhibition of apoptosis, angiogenesis and cell invasion. The aims of this review are to provide an overview of the multi functional roles of the hnRNPs, and how such roles implicate this family as regulators of tumour development. The different stages of tumour development that are potentially regulated by the hnRNPs along with their aberrant expression profiles in tumour tissues will also be discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16378690     DOI: 10.1016/j.bbcan.2005.10.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  84 in total

1.  c-Myc regulates RNA splicing of the A-Raf kinase and its activation of the ERK pathway.

Authors:  Jens Rauch; Kim Moran-Jones; Valerie Albrecht; Thomas Schwarzl; Keith Hunter; Olivier Gires; Walter Kolch
Journal:  Cancer Res       Date:  2011-04-21       Impact factor: 12.701

2.  TERRA transcripts are bound by a complex array of RNA-binding proteins.

Authors:  Isabel López de Silanes; Martina Stagno d'Alcontres; Maria A Blasco
Journal:  Nat Commun       Date:  2010-06-29       Impact factor: 14.919

3.  BRCA1 modulates the expression of hnRNPA2B1 and KHSRP.

Authors:  Manuela Santarosa; Laura Del Col; Alessandra Viel; Nicoletta Bivi; Chiara D'Ambrosio; Andrea Scaloni; Gianluca Tell; Roberta Maestro
Journal:  Cell Cycle       Date:  2010-12-01       Impact factor: 4.534

4.  Replication error deficient and proficient colorectal cancer gene expression differences caused by 3'UTR polyT sequence deletions.

Authors:  Jennifer L Wilding; Simon McGowan; Ying Liu; Walter F Bodmer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-19       Impact factor: 11.205

5.  Identification of a heterogeneous nuclear ribonucleoprotein-recognition region in the HIV Rev protein.

Authors:  Kamyar Hadian; Michelle Vincendeau; Nina Mäusbacher; Daniel Nagel; Stefanie M Hauck; Marius Ueffing; Abraham Loyter; Thomas Werner; Horst Wolff; Ruth Brack-Werner
Journal:  J Biol Chem       Date:  2009-10-05       Impact factor: 5.157

6.  MRPL33 and its splicing regulator hnRNPK are required for mitochondria function and implicated in tumor progression.

Authors:  L Liu; C Luo; Y Luo; L Chen; Y Liu; Y Wang; J Han; Y Zhang; N Wei; Z Xie; W Wu; G Wu; Y Feng
Journal:  Oncogene       Date:  2017-09-04       Impact factor: 9.867

7.  Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53.

Authors:  Renyuan Zhou; Reneé Shanas; Mark A Nelson; Achyut Bhattacharyya; Jiaqi Shi
Journal:  Int J Cancer       Date:  2010-01-15       Impact factor: 7.396

8.  Quantitative analysis of brain nuclear phosphoproteins identifies developmentally regulated phosphorylation events.

Authors:  Lujian Liao; Daniel B McClatchy; Sung Kyu Park; Tao Xu; Bingwen Lu; John R Yates
Journal:  J Proteome Res       Date:  2008-09-30       Impact factor: 4.466

9.  Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes.

Authors:  Jean-Philippe Gagné; Maxim Isabelle; Ken Sin Lo; Sylvie Bourassa; Michael J Hendzel; Valina L Dawson; Ted M Dawson; Guy G Poirier
Journal:  Nucleic Acids Res       Date:  2008-11-03       Impact factor: 16.971

10.  Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer.

Authors:  P Barboro; E Repaci; A Rubagotti; S Salvi; S Boccardo; B Spina; M Truini; C Introini; P Puppo; N Ferrari; G Carmignani; F Boccardo; C Balbi
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.